tbuckley/cabot-search huggingface dataset:
Tracking Postoperative Recovery—Making a Case for Smartphone Technology
Authors: Julio F. Fiore, Liane S. Feldman
Journal: JAMA Surgery (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
P1.14-41 The Combination of the PARP Inhibitor Olaparib and the ATR Inhibitor VE-821 Selectively Targets ATM-Deficient Lung Cancer Cells
Authors: N. Jette, S. Radhamani, G. Arthur, R. Ye, S. Goutam, A. Boylos, L. Petersen, P. Bose, G. Bebb, S. Lees-Miller
Journal: Journal of Thoracic Oncology (2019)
P1.06-12 Defects in Homologous Recombination Repair Indicates Susceptibility for Olaparib Treatment in Malignant Pleural Mesothelioma
Authors: S. Borchert, M. Wessolly, J. Schmeller, E. Mairinger, J. Kollmeier, T. Hager, T. Mairinger, T. Herold, D. Christoph, R. Walter, W. Eberhardt, T. Plönes, J. Wohlschlaeger, C. Aigner, K. Schmid, F. Mairinger
Journal: Journal of Thoracic Oncology (2019)
P2.03-26 Elucidating Mechanisms of Resistance to Targeted Therapies in Mutant EGFR or KRAS Driven Lung Adenocarcinoma Harboring Dual Loss of p53 and RB1
Authors: Y. Inoue, R. Somwar, M. Ladanyi, W. Lockwood
Journal: Journal of Thoracic Oncology (2019)
PD01.05 CANOPY-1: Phase 3 Study of Canakinumab/Placebo+Pembrolizumab+Platinum-Chemotherapy in Untreated Stage IIIB-IV NSCLC Patients
Authors: B.E. Johnson, G.D. Castro, A. Greystoke, B. Solomon, D.S.W. Tan, V. Passos, S. Deudon, A.L. Louveau, E. Felip
Journal: Journal of Thoracic Oncology (2019)
Total Therapy 3 (TT3) Incorporating VelcadeR (V) Intro Upfront Management of Multiple Myeloma (MM): Comparison with TT2 + Thalidomide (T).
Authors: Bart Barlogie, Guido Tricot, Erik Rasmussen, Elias Anaissie, Frits van Rhee, Maurizio Zangari, Klaus Hollmig, Joshua Epstein, John Shaughnessy, John Crowley
Journal: Blood (2005)
OA13.06 Surgical Outcomes Following Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Non-Small Cell Lung Cancer - NEOSTAR Study
Authors: B. Sepesi, T. Cascone, W. William, H. Lin, C. Leung, A. Weissferdt, G. Walsh, D. Rice, J. Roth, R. Mehran, W. Hofstetter, M. Antonoff, F. Fossella, F. Mott, X. Le, F. Skoulidis, J. Zhang, L. Byers, V. Lam, B. Glisson, J. Kurie, G. Blumenschein, A. Tsao, C. Lu, M. Altan, Y. Elamin, D. Gibbons, V. Papadimitrakopoulou, J. Lee, J. Heymach, A. Vaporciyan, S. Swisher
Journal: Journal of Thoracic Oncology (2019)
IMAGE: high-powered detection of genetic effects on DNA methylation using integrated methylation QTL mapping and allele-specific analysis
Authors: Yue Fan, Tauras P. Vilgalys, Shiquan Sun, Qinke Peng, Jenny Tung, Xiang Zhou
Journal: Genome biology (2019)

Abstract Identifying genetic variants that are associated with methylation variation—an analysis commonly referred to as methylation quantitative trait locus (mQTL) mapping—is important for understanding the epigenetic mechanisms underlying genotype-trait associations. Here, we develop a statistical method, IMAGE, for mQTL mapping in sequencing-based methylation studies. IMAGE properly accounts for the count nature of bisulfite sequencing data and incorporates allele-specific methylation patterns from heterozygous individuals to enable more powerful mQTL discovery. We compare IMAGE with existing approaches through extensive simulation. We also apply IMAGE to analyze two bisulfite sequencing studies, in which IMAGE identifies more mQTL than existing approaches.
Modeling the Placenta with Stem Cells
Authors: Toshihiko Ezashi, Danny J. Schust, Laura C. Schulz
Journal: New England Journal of Medicine (2019)

Placental health is critical to fetal health, but modeling the placenta is difficult. A recent study shows that both human and porcine stem-cell cultures can, in fact, be efficiently differentiated into trophoblasts and also converted into trophoblast stem cells.
Caring for long term health needs in women with a history of sexual trauma
Authors: Veronica Ades, Brian Goddard, Savannah Pearson Ayala, Judy A Greene
Journal: BMJ (2019)

### What you need to know Globally, about 30% of women report intimate partner violence (physical, sexual, or both) (95% confidence interval 27.8% to 32.2%) and about 7.2% (95% confidence interval 5.3% to9.1%) of women face non-partner sexual violence in their lifetime.1 Sexual violence in men is less studied. In the United States, the National Intimate Partner and Sexual Violence Survey determined a lifetime prevalence of contact sexual violence (including forced penetration and fondling) of 36.3% (95% confidence interval 35.3% to 37.2%) among women and 17.1% (95% confidence interval 16.3% to 17.9%) among men.2 Experiences of sexual violence negatively affect a person's long term physical and psychological wellbeing as well as their interaction with the healthcare system. Most guidelines focus on treatment in the acute setting in the immediate aftermath of sexual assault, and rarely address long term care. Box 1 lists key aspects of acute medical care for people who have experienced sexual violence. Box 1 ### Summary of acute care for people who have experienced sexual assault345RETURN TO TEXT
OA07.05 High-Grade Chemotherapy-Induced Peripheral Neuropathy (CIPN): An Analysis of ECOG-ACRIN Lung Cancer Clinical Trials
Authors: S. Rashdan, S. Dahlberg, D. Gerber, A. Sandler, J. Schiller, D. Johnson, S. Ramalingam
Journal: Journal of Thoracic Oncology (2019)
Amino Acids License Kinase mTORC1 Activity and Treg Cell Function via Small G Proteins Rag and Rheb
Authors: Hao Shi, Nicole M. Chapman, Jing Wen, Cliff Guy, Lingyun Long, Yogesh Dhungana, Sherri Rankin, Stephane Pelletier, Peter Vogel, Hong Wang, Junmin Peng, Kun-Liang Guan, Hongbo Chi
Journal: Immunity (2019)
EP1.09-05 Correlation of ROS1 (D4D6) Immunohistochemistry with ROS1 FISH Analysis in Lung Adenocarcinoma: Is IHC a Reliable Screening Tool?
Authors: S. Sharma, A. Dewan, L. Kini, M. Bhardwaj, S. Kumar, D. Sharma, B. Yadav, R. Pandey, K. Gogai
Journal: Journal of Thoracic Oncology (2019)
Adenovirus Vector-Based Vaccines Confer Maternal-Fetal Protection against Zika Virus Challenge in Pregnant IFN-αβR−/− Mice
Authors: Rafael A. Larocca, Erica A. Mendes, Peter Abbink, Rebecca L. Peterson, Amanda J. Martinot, Mark Justin Iampietro, Zi H. Kang, Malika Aid, Marinela Kirilova, Catherine Jacob-Dolan, Lisa Tostanoski, Erica N. Borducchi, Rafael A. De La Barrera, Dan H. Barouch
Journal: Cell Host & Microbe (2019)
P1.04-58 Uncovering the Tumor Microenvironment of KRAS-Driven Lung Adenocarcinoma: The Link Between Th17 Signaling and B Cell
Authors: S. De Summa, D. Petriella, R. Lacalamita, D. Galetta, M. Montrone, A. Catino, P. Pizzutilo, M.A. Botticella, F.A. Zito, M. Zambetti, A. Zonno, R. Pinto, S. Tommasi
Journal: Journal of Thoracic Oncology (2019)
OA01.03 Probability Model for Malignancy in Hilar and Mediastinal Lymph Nodes in Lung Cancer Based on PET-CT and EBUS
Authors: J. Bordas-Martinez, J.L. Vercher Conejero, G. Rodríguez Gonzalez, P. Notta, C. Tebé Cordomi, C. Martín Cabeza, N. Cubero De Frutos, M.R. López-Lisbona, M. Díez-Ferrer, N. Baixeras Gonzalez, C. Gamez Cenzano, J. Dorca Sargatal, A. Rosell
Journal: Journal of Thoracic Oncology (2019)
P2.14-67 Metastatic RET-Rearranged Lung Adenocarcinomas Treated with Alectinib: Retrospective Analysis of a Single Institution
Authors: M. Ribeiro, A. Gongora, L. Oliveira, J.V. Alessi, K. Saccardo, B. Zucchetti, F. Barbosa, D. Muniz, A. Shimada, C. De Souza, O. Feher, A. Katz
Journal: Journal of Thoracic Oncology (2019)
P1.18-10 The Prognostic Impact of the Extent of Nodal Involvement in NSCLC Treated with Radical Chemoradiation
Authors: C. Yip, S.H. Tan, K. Chua, T.R. Siow, A. Thiagarajan, K.W. Fong, S.P. Yap, W.L. Ng, B.S.H. Chia, J. Tan
Journal: Journal of Thoracic Oncology (2019)
EP1.16-37 Correlation of Serum Albumin and CRP Levels with Chemotherapy Toxicity in Patients of Metastatic Lung Cancer
Authors: S. Saldanha, L. N, L. D, L. Jacob, S. Babu, R. H, R. Lakkavalli, A. Thottian
Journal: Journal of Thoracic Oncology (2019)
Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura
Authors: Marie Scully, Jessica Minkue Mi Edou, Filip Callewaert
Journal: New England Journal of Medicine (2019)

Comment in Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. Reply - Comment On: N Engl J Med. 2019 Jan 24;380(4):335-346 [30625070]
First-in-Human Experience With Sirolimus-Eluting Self-Expanding Stent for Femoropopliteal Lesions
Authors: Sabine Steiner, Antoine Sauguet, Ralf Langhoff, Andrea Kahlberg, Marcus Thieme, Thomas Zeller, Philippe Garot, Philippe Commeau, Alberto Cremonesi, Enrico Maria Marone, Dierk Scheinert
Journal: Journal of the American College of Cardiology (2019)
EP1.14-16 Use of Digital Droplet PCR for Detecting EGFR T790M Resistance Mutation in Plasma at Progression on TKI Therapy
Authors: M. Jönsson, M. Planck, C. Reuterswärd, I. Nilsson, M. Carlsson, A. George, L. Saal, J. Staaf, S. Isaksson
Journal: Journal of Thoracic Oncology (2019)
EP1.01-63 The Usefulness of “Serum” Samples to Detect EGFR T790M Mutation in EGFR-TKI-Resistant Non-Small Cell Lung Cancer
Authors: K. Kobayashi, K. Naoki, S. Ikemura, H. Yasuda, I. Kawada, K. Soejima
Journal: Journal of Thoracic Oncology (2019)
Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy
Authors: Hao Liu, Zhen Zhao, Li Zhang, Yuanke Li, Akshay Jain, Ashutosh Barve, Wei Jin, Yanli Liu, John Fetse, Kun Cheng
Journal: Journal for ImmunoTherapy of Cancer (2019)

Immunotherapy using checkpoint inhibitors, especially PD-1/PD-L1 inhibitors, has now evolved into the most promising therapy for cancer patients. However, most of these inhibitors are monoclonal antibodies, and their large size may limit their tumor penetration, leading to suboptimal efficacy. As a result, there has been a growing interest in developing low-molecular-weight checkpoint inhibitors.We developed a novel biopanning strategy to discover small peptide-based anti-PD-L1 inhibitors. The affinity and specificity of the peptides to PD-L1 were examined using various assays. Three-dimensional (3D) spheroid penetration study was performed to determine the tumor penetration capability of the peptides. Anti-tumor activity of the peptides was evaluated in mice bearing CT26 tumor cells.We discover several anti-PD-L1 peptide inhibitors to block PD-1/PD-L1 interaction. The peptides exhibit high affinity and specificity to human PD-L1 protein as well as PD-L1-overexpressing human cancer cells MDA-MB-231 and DU-145. Molecular docking studies indicate that the peptide CLP002 specifically binds to PD-L1 at the residues where PD-L1 interacts with PD-1. The peptide also blocks the CD80/PD-L1 interaction, which may further enhance the immune response of tumor-infiltrating T cells. Compared to antibody, the peptide CLP002 exhibits better tumor penetration in a 3D tumor spheroid model. The peptide CLP002 restores proliferation and prevents apoptosis of T cells that are co-cultured with cancer cells. The peptide CLP002 also inhibits tumor growth and increases survival of CT26 tumor-bearing mice.This study demonstrated the feasibility of using phage display to discover small peptide-based checkpoint inhibitors. Our results also suggested that the anti-PD-L1 peptide represents a promising low-molecular-weight checkpoint inhibitor for cancer immunotherapy.
P2.04-89 Neoadjuvant Pembrolizumab in Early Stage Non-Small Cell Lung Cancer (NSCLC): Toxicity, Efficacy, and Surgical Outcomes
Authors: N. Ready, B. Tong, J. Clarke, L. Gu, D. Wigle, K. Dragnev, T. Sporn, T. Stinchcombe, T. D’Amico
Journal: Journal of Thoracic Oncology (2019)
EP1.03-21 Circulating Tumor Cells Isolation Is Not a Useful Prognostic Tool for Non-Small Cell Lung Cancer Patients Candidates to Surgical Treatment
Authors: L. Milla Collado, C. Fraile Olivero, C. Cerdan Santacruz, T. Valverde Higueras, I. Cal Vazquez, J. Jarabo Sarceda, E. Fernández Martín, J.L. Gonzalez Larriba, F. Hernando-Trancho
Journal: Journal of Thoracic Oncology (2019)
P1.17-26 Delivery of Stereotactic MR-Guided Adaptive Radiation Therapy for Peripheral Lung Tumors
Authors: T. Finazzi, M. Palacios, C. Haasbeek, M. Admiraal, F. Spoelstra, A. Bruynzeel, B. Slotman, F. Lagerwaard, S. Senan
Journal: Journal of Thoracic Oncology (2019)
MA08.02 Durvalumab Impact in the Treatment Strategy of Stage III Non-Small Cell Lung Cancer (NSCLC): An EORTC Young Investigator Lung Cancer Group Survey
Authors: M. Giaj Levra, J. Benet, B. Hasan, T. Berghmans, A. Bruni, A.M. Dingemans, N. Giaj Levra, J. Edwards, C. Faivre-Finn, N. Girard, E. Gobbini, L. Greillier, L. Hendriks, S. Lantuejoul, A. Levy, S. Novello, M. O'Brien, M. Reck, A. Pochesci, J. Menis, B. Besse
Journal: Journal of Thoracic Oncology (2019)
P1.03-31 BRAF Mutations: Classes I, II and III in NSCLC Patients Included in the SLLIP Trial, Targeted Treatment According to Class
Authors: J. Bracht, N. Karachaliou, T. Bivona, M. Fernández-Bruno, J. Berenguer, M. Gonzalez-Cao, R. Lanman, I. Faull, R. Nagy, A. Drozdowskyj, A. Aguilar Hernandez, J.J. Garcia Mosquera, M.A. Molina-Vila, R. Rosell
Journal: Journal of Thoracic Oncology (2019)
Abstract 14985: Genetic Deficiency of the H2S Producing Enzyme, 3-Mercaptopyruvate Sulfurtransferase, Exacerbates Pressure-Overload Induced Heart Failure
Authors: Zhen Li, Jean Carnal, Noriyuki Nagahara, David J Lefer
Journal: Circulation (2018)

Background: Hydrogen sulfide (H2S) is produced endogenously by Cystathionine γ-lyase (CSE), Cystathionine β-synthase, and 3-Mercaptopyruvate Sulfurtransferase (3MST). H2S is a critical mediator for...
P1.11-15 Feasibility of a Lung Health Clinic for Early Lung Cancer Identification in High-Risk Individuals in South-East London
Authors: A. Nair, A. Saleem, G. Selman, H. Kerslake, R. Breen, S. Ho, S.M. Mak, Y. Akande, J. Turville, T. Rua, J. Peacock, G. Santis, R. Razavi
Journal: Journal of Thoracic Oncology (2019)
The Realities of External Validity in Global Surgery Research
Authors: Seth D. Goldstein
Journal: JAMA Surgery (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
P2.01-54 Real-World PD-L1 Testing Patterns for Patients with Advanced Non-Small Cell Lung Cancer in Greece
Authors: E. Kokkotou, A. Charpidou, A. Papaspiliou, L. Stournara, V. Grammatikou, F. Ejzykowicz, K. Syrigos
Journal: Journal of Thoracic Oncology (2019)
EP1.01-84 Second Line Treatment with Docetaxel/Nintedanib in Patients with Metastatic Non Small Cell Lung Adenocarcinoma-Preliminary Results
Authors: T. Tegos, N. Alevizopoulos, K. Folinas, M. Pavlakis, K. Gioti, V. Edvin, V. Nikolaidou, C. Stathopoulos, V. Sioufi, M. Vaslamatzis
Journal: Journal of Thoracic Oncology (2019)
EP1.16-02 Proactively Improving the Management of Immune-Related Adverse Events (irAEs) in a Community Cancer Program
Authors: L. Dobrea, E. Esposito Nguyen, J. Maurice, M. Carandang, D. Boyd, S. Haimowitz, L. Gracie-King, J. Kim
Journal: Journal of Thoracic Oncology (2019)
Effect of Frequency of Changing Point-of-Use Reminder Signs on Health Care Worker Hand Hygiene Adherence
Authors: Mark W. Vander Weg, Eli N. Perencevich, Amy M. J. O’Shea, Michael P. Jones, Mary S. Vaughan Sarrazin, Carrie L. Franciscus, Cassie Cunningham Goedken, Gio J. Baracco, Suzanne F. Bradley, Jose Cadena, Graeme N. Forrest, Kalpana Gupta, Daniel J. Morgan, Michael A. Rubin, Joseph Thurn, Marvin J. Bittner, Heather Schacht Reisinger
Journal: JAMA Network Open (2019)

Although hand hygiene (HH) is considered the most effective strategy for preventing hospital-acquired infections, HH adherence rates remain poor.To examine whether the frequency of changing reminder signs affects HH adherence among health care workers.This cluster randomized clinical trial in 9 US Department of Veterans Affairs acute care hospitals randomly assigned 58 inpatient units to 1 of 3 schedules for changing signs designed to promote HH adherence among health care workers: (1) no change; (2) weekly; and (3) monthly. Hand hygiene rates among health care workers were documented at entry and exit to patient rooms during the baseline period from October 1, 2014, to March 31, 2015, of normal signage and throughout the intervention period of June 8, 2015, to December 28, 2015. Data analyses were conducted in April 2018.Hospital units were randomly assigned into 3 groups: (1) no sign changes throughout the intervention period, (2) signs changed weekly, and (3) signs changed monthly.Hand hygiene adherence as measured by covert observation. Interrupted time series analysis was used to examine changes in HH adherence from baseline through the intervention period by group.Among 58 inpatient units, 19 units were assigned to the no change group, 19 units were assigned to the weekly change group, and 20 units were assigned to the monthly change group. During the baseline period, 9755 HH opportunities were observed at room entry and 10 095 HH opportunities were observed at room exit. During the intervention period, a total of 15 855 HH opportunities were observed at room entry, and 16 360 HH opportunities were observed at room exit. Overall HH adherence did not change from baseline compared with the intervention period at either room entry (4770 HH events [48.9%] vs 3057 HH events [50.1%]; P = .14) or exit (6439 HH events [63.8%] vs 4087 HH events [65.2%]; P = .06). In units that changed signs weekly, HH adherence declined from baseline at room entry (-1.9% [95% CI, -2.7% to -0.8%] per week; P < .001) and exit (-0.8% [95% CI, -1.5% to 0.1%] per week; P = .02). No significant changes in HH adherence were observed in other groups.The frequency of changing reminder signs had no effect on HH rates overall. Units assigned to change signs most frequently demonstrated worsening adherence. Considering the abundance of signs in the acute care environment, the frequency of changing signs did not appear to provide a strong enough cue by itself to promote behavioral change.ClinicalTrials.gov Identifier: NCT02223455.
P1.14-50 A Phase 2 Trial of Cabozantinib in ROS1-Rearranged Lung Adenocarcinoma
Authors: R. Guo, I. Preeshagul, A. Schoenfeld, C. Mccarthy, A. Makhnin, A. Plodkowski, M. Ginsberg, M. Davare, L. Delasos, R. Somwar, M. Arcila, G. Riely, N. Rekhtman, M. Ladanyi, M. Kris, A. Drilon
Journal: Journal of Thoracic Oncology (2019)
A Bayesian meta-analysis of the prognostic value of circulating HER2/neu levels in breast cancer (BC) patients.
Authors: Walter P. Carney, Robert Thiel, Dirk Bernhardt, Suhail M. Ali, Kim Leitzel, Allan Lipton
Journal: Journal of Clinical Oncology (2013)

643 Background: Many reports have shown the prognostic value of HER-2 measured in tumor tissue or in blood. In 2009, Finn et.al. showed that in a study of 579 MBC patients whose serum HER-2 levels (sHER-2) were constantly below normal had a longer PFS than patients with a sHER-2 level constantly above normal. Patients who converted from above normal to less than normal during therapy had a longer PFS than the opposite change. Methods: We performed a Bayesian meta-analysis of 12 studies where all sHER-2 levels were measured using an FDA cleared sHER-2 test with a standard cutoff of 15ng/ml. We chose a Bayesian approach because a “meta-analysis” is a natural extension of the Bayesian view that current knowledge is the result of prior knowledge modified by the data. After an in depth literature search, we selected 12 publications based on the following criteria. Baseline levels were available from either early stage or late stage patients who had at least a 2 year disease free or progression free survival as indicated by a Kaplan-Meier (K-M) curve. Results: The analysis included 4030 BC patients of which 1106 patients had baseline levels &lt; 15ng/ml and 2924 patients had baseline values &gt;15ng/ml. From the K-M curves, we estimated the number of recurrences up to 24 months in each group and prepared a 2x2 table for each study. We determined the odds ratio (OR) for the 12 studies which ranged from 0.57 to 74. A posterior distribution for the aggregated 12 studies can be represented by a Dirichlet distribution. 10,000 estimates of the aggregated OR indicated that there is a 95% credibility that the odds of a woman with baseline sHER-2 &gt;15ng/ml recurring at or before two years is between 3.39 and 4.57 times higher than the odds of a woman whose baseline sHER-2 was &lt; 15ng/ml recurring at or before two years. Conclusions: This meta-analysis agrees with previous studies that serum HER-2 levels &gt; 15ng/ml can be a strong prognostic indicator for women with Breast Cancer and that managing therapy regimens to maximize the decrease in serum HER-2 levels could be important target in treating patients.
OA07.03 Clinical Outcome of Non-Small Cell Lung Cancer with EGFR/HER2 Exon 20 Insertions Identified in the LC-SCRUM-Japan
Authors: H. Udagawa, S. Matsumoto, Y. Ohe, M. Satouchi, N. Furuya, Y.H. Kim, T. Seto, K. Soejima, D. Hayakawa, T. Kato, S. Miyamoto, K. Ohashi, S. Saeki, H. Ohta, D. Fujimoto, A. Sekine, K. Yoh, K. Goto
Journal: Journal of Thoracic Oncology (2019)